386 related articles for article (PubMed ID: 28127991)
1. TSHR as a therapeutic target in Graves' disease.
Smith TJ
Expert Opin Ther Targets; 2017 Apr; 21(4):427-432. PubMed ID: 28127991
[TBL] [Abstract][Full Text] [Related]
2. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy.
Janssen JAMJL; Smith TJ
Cells; 2021 Feb; 10(2):. PubMed ID: 33673340
[TBL] [Abstract][Full Text] [Related]
3. The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy.
Smith TJ
Eye (Lond); 2019 Feb; 33(2):200-205. PubMed ID: 30385883
[TBL] [Abstract][Full Text] [Related]
4. Insulin-Like Growth Factor Pathway and the Thyroid.
Smith TJ
Front Endocrinol (Lausanne); 2021; 12():653627. PubMed ID: 34149612
[TBL] [Abstract][Full Text] [Related]
5. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?
Wiersinga WM
J Clin Endocrinol Metab; 2011 Aug; 96(8):2386-94. PubMed ID: 21677036
[TBL] [Abstract][Full Text] [Related]
6. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
Smith TJ; Hegedüs L; Douglas RS
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):291-302. PubMed ID: 22632366
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.
Smith TJ; Janssen JAMJL
Endocr Rev; 2019 Feb; 40(1):236-267. PubMed ID: 30215690
[TBL] [Abstract][Full Text] [Related]
8. Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy.
Smith TJ
Annu Rev Pharmacol Toxicol; 2019 Jan; 59():129-148. PubMed ID: 30044728
[TBL] [Abstract][Full Text] [Related]
9. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.
Tsui S; Naik V; Hoa N; Hwang CJ; Afifiyan NF; Sinha Hikim A; Gianoukakis AG; Douglas RS; Smith TJ
J Immunol; 2008 Sep; 181(6):4397-405. PubMed ID: 18768899
[TBL] [Abstract][Full Text] [Related]
10. A cyclic peptide significantly improves thyroid function, thyrotropin-receptor antibodies and orbital mucine /collagen content in a long-term Graves' disease mouse model.
Diana T; Ungerer M; Wüster C; Faßbender J; Li Z; Reimann A; Holthoff HP; Kanitz M; Kahaly GJ
J Autoimmun; 2021 Aug; 122():102666. PubMed ID: 34144327
[TBL] [Abstract][Full Text] [Related]
11. Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy.
Ryder M; Wentworth M; Algeciras-Schimnich A; Morris JC; Garrity J; Sanders J; Young S; Sanders P; Furmaniak J; Rees Smith B
Thyroid; 2021 Oct; 31(10):1597-1602. PubMed ID: 34114495
[No Abstract] [Full Text] [Related]
12. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
Morshed SA; Ma R; Latif R; Davies TF
Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
[No Abstract] [Full Text] [Related]
13. Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy.
Ding Y; Yang S; Gao H
Horm Metab Res; 2021 Apr; 53(4):211-218. PubMed ID: 33853117
[TBL] [Abstract][Full Text] [Related]
14. IGF1 receptor and thyroid-associated ophthalmopathy.
Mohyi M; Smith TJ
J Mol Endocrinol; 2018 Jul; 61(1):T29-T43. PubMed ID: 29273685
[TBL] [Abstract][Full Text] [Related]
15. Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies.
Davies TF; Latif R
Expert Opin Ther Targets; 2015 Jun; 19(6):835-47. PubMed ID: 25768836
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy.
Paik JS; Kim SE; Kim JH; Lee JY; Yang SW; Lee SB
Immunobiology; 2020 Mar; 225(2):151902. PubMed ID: 31899052
[TBL] [Abstract][Full Text] [Related]
17. Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy.
Smith TJ; Janssen JA
Front Endocrinol (Lausanne); 2016; 7():167. PubMed ID: 28096798
[TBL] [Abstract][Full Text] [Related]
18. The putative role of fibroblasts in the pathogenesis of Graves' disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation.
Smith TJ
Autoimmunity; 2003; 36(6-7):409-15. PubMed ID: 14669949
[TBL] [Abstract][Full Text] [Related]
19. Is There Evidence for IGF1R-Stimulating Abs in Graves' Orbitopathy Pathogenesis?
Krieger CC; Neumann S; Gershengorn MC
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911689
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
Wall JR; Lahooti H
Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
